Medication Profile—Long-Term Care
Date of admission: 7/15
Patient Name: Marla Pass
Race: Black
Address: 545 Somewhere St.
Height: 6'1”
Age: 58
Weight: 230 lb
Gender: F
Allergies: NKA

Diagnosis
Primary: Crohn's disease  
Secondary: Low back pain, osteoarthritis, osteoporosis, and urinary incontinence, dry eyes, constipation

Admission orders
 
Date
Name and Strength
Route
Sig
1.
7/26
Theragran-M®
PO
i qd
2.
7/26
Purinethol® 25 mg
PO
i qd
3.
7/26
Feosol® 325 mg
PO
i qd
4.
7/26
Ascorbic acid 500 mg
PO
i qd
5.
7/26
Oyst-Cal 500
PO
i qd
6.
7/26
Ultram® 50 mg
PO
i bid
7.
7/26
Lovenox® 30 mg
PO
i bid
8.
7/26
Milk of magnesia 30 cc
PO
i qd prn constipation
9.
7/26
Tylenol® Gelcaps
PO
i tid
10.
7/26
Tears Natural II
Ophthalmic
i gtt ou tid
11.
7/26
Skelaxin® 400 mg
PO
i tid
12.
7/26
Colazal® 750 mg
PO
iii tid
13.
7/26
Fosamax® 70 mg
PO
i at 7 am qwk
14.
7/26
Rowasa® 500 mg supp
PR
i bid
15.
726
Tylenol® 650 mg
PO
i q3-4h prn
16.
7/26
Roxicet®
PO
i-ii PO q4-6h prn
17.
7/26
Deltasone® 5 mg
PO
i qd
18.
7/26
Detrol® 4 mg
PO
i qd

Notes and patient information
1.     Fall precautions

Use the patient profile above to answer the following questions.

1.
How many of the drugs listed in Ms. Pass's medication profile are indicated for the treatment for Crohn's disease?
A.
1
B.
2
C.
4
D.
6
E.
9


2.
What is the pharmacologic classification of Skelaxin®?
I. Skeletal muscle relaxant
II. Antianxiety agent
III. Anticonfulsant
A.
I only
B.
II only
C.
III only
D.
I and II
E.
II and III


3.
This patient is currently taking Colazal® to treat her
I. Osteoarthritis
II. Osteoporosis
III. Crohn's disease
A.
I only
B.
II only
C.
III only
D.
I and II
E.
II and III


4.
Roxicet® is a combination of which two drugs?
A.
Acetaminophen and codeine
B.
Acetaminophen and pseudoephedrine
C.
Oxycodone and aspirin
D.
Oxycodone and acetaminophen
E.
Morphine and acetaminophen


5.
Additional agents that are indicated to treat Crohn's disease but that are not listed in this patient's profile include
I. Imuran®
II. Remicade®
III. Cytoxan®
A.
I only
B.
II only
C.
III only
D.
I and II
E.
II and III


6.
Which of the following statements are true about Crohn's disease?
I. Steroids can prevent the recurrence of Crohn's disease
II. The major agents used for maintenance of remission of Crohn's disease are sulfasalazine and mesalamine derivatives
III. Ulcerative colitis and Crohn's disease are exactly the same type of disease
A.
I only
B.
II only
C.
III only
D.
I and II
E.
I, II, and III


7.
Nonpharmacologic approaches for the treatment of osteoporosis include
I. Decreasing caffeine ingestion to less than 2–5 cups of coffee
II. Performing aerobic and strengthening exercises
III. Discontinue smoking
A.
I only
B.
II only
C.
III only
D.
I and II
E.
I, II, and III


8.
Which of the drugs listed in Ms. Pass's medication profile should not be administered within 4 hours of her taking Roxicet®?
I. Rowasa®
II. Tylenol®
III. Skelaxin®
A.
I only
B.
II only
C.
III only
D.
I and II
E.
II and III


9.
The benefits of administering calcium supplements to patients diagnosed with osteoporosis include
I. Decrease in bone resorption
II. Increase in bone resorption
III. Increase in bone mass
A.
I only
B.
II only
C.
III only
D.
I and III
E.
II and III


10.
Drugs that should not be taken concomitantly with Ultram® include
I. Roxicet®
II. Tylenol®
III. Skelaxin®
A.
I only
B.
II only
C.
III only
D.
I and II
E.
II and III


STOP This is the end of the test. When you have completed all the questions and reviewed your answers, press the button below to grade the test.